The noninflammatory role of high mobility group box 1/toll‐like receptor 2 axis in the self‐renewal of mammary cancer stem cells

Cancer stem cells (CSCs) are responsible for tumor progression, metastases, resistance to therapy, and tumor recurrence. Therefore, the identification of molecules involved in CSC self‐renewal is a necessary step toward more effective therapies. To this aim, through the transcription profiling of the murine ErbB2+ tumor cell line TUBO vs. derived CSC‐enriched mammospheres, Toll‐like receptor 2 (TLR2) was identified as 2‐fold overexpressed in CSCs, as confirmed by qPCR and cytofluorimetric analysis. TLR2 signaling inhibition impaired in vitro mammosphere generation in murine TUBO (60%) and 4T1 (30%) and human MDA‐MB‐231 (50%), HCC1806 (60%), and MCF7 (50%) cells. In CSC, TLR2 was activated by endogenous high‐mobility‐group box 1 (HMGB1), inducing IκBα phosphorylation, IL‐6 and TGFβ secretion, and, consequently, STAT3 and Smad3 activation. In vivo TLR2 inhibition blocked TUBO tumor takes in 9/14 mice and induced a 2‐fold reduction in lung metastases development by decreasing cell proliferation and vascularization and increasing apoptosis. Collectively, these results demonstrate that murine and human mammary CSCs express TLR2 and its ligand HMGB1; this autocrine loop plays a pivotal role in CSC self‐renewal, tumorigenesis, and metastatic ability. These findings, while providing evidence against the controversial use of TLR2 agonists in antitumor therapy, lay out new paths toward the design of anticancer treatments.—Conti, L., Lanzardo, S., Arigoni, M., Antonazzo, R., Radaelli, E., Cantarella, D., Calogero, R. A., Cavallo, F., The noninflammatory role of high mobility group box 1/toll‐like receptor 2 axis in the self‐renewal of mammary cancer stem cells. FASEB J. 27, 4731–4744 (2013). www.fasebj.org

[1]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[2]  Giovanni Parmigiani,et al.  A Cross-Study Comparison of Gene Expression Studies for the Molecular Classification of Lung Cancer , 2004, Clinical Cancer Research.

[3]  K. Tracey,et al.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Federica Cavallo,et al.  Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. , 2008, Neoplasia.

[5]  F. Giancotti,et al.  Cell cycle and adhesion defects in mice carrying a targeted deletion of the integrin β4 cytoplasmic domain , 1998 .

[6]  G. Botti,et al.  Triple negative breast cancer: from molecular portrait to therapeutic intervention. , 2010, Critical reviews in eukaryotic gene expression.

[7]  Max S Wicha,et al.  Cancer stem cells: an old idea--a paradigm shift. , 2006, Cancer research.

[8]  A. Parker,et al.  STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. , 2012, Cancer cell.

[9]  Yafang Huang,et al.  Bacteria Peptidoglycan Promoted Breast Cancer Cell Invasiveness and Adhesiveness by Targeting Toll-Like Receptor 2 in the Cancer Cells , 2010, PloS one.

[10]  P. Rovere-Querini,et al.  HMGB1: a two-headed signal regulating tumor progression and immunity. , 2008, Current opinion in immunology.

[11]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[12]  Sean J Morrison,et al.  Cancer stem cells: impact, heterogeneity, and uncertainty. , 2012, Cancer cell.

[13]  J. A. Nogueira-Machado,et al.  HMGB-1 as a target for inflammation controlling. , 2012, Recent patents on endocrine, metabolic & immune drug discovery.

[14]  Tae Woo Kim,et al.  Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. , 2012, Cancer research.

[15]  Piero Musiani,et al.  Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.

[16]  Danila Coradini,et al.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. , 2005, Cancer research.

[17]  Yongliang Xu,et al.  Gene Silencing of Toll-Like Receptor 2 Inhibits Proliferation of Human Liver Cancer Cells and Secretion of Inflammatory Cytokines , 2012, PloS one.

[18]  Jie Fan TLR Cross-Talk Mechanism of Hemorrhagic Shock-Primed Pulmonary Neutrophil Infiltration. , 2009, The open critical care medicine journal.

[19]  A. Hinck,et al.  Blockade of Autocrine TGF-β Signaling Inhibits Stem Cell Phenotype, Survival, and Metastasis of Murine Breast Cancer Cells. , 2012, Journal of stem cell research & therapy.

[20]  E. Podrez,et al.  Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands , 2010, Nature.

[21]  Francesca Cordero,et al.  oneChannelGUI: a graphical interface to Bioconductor tools, designed for life scientists who are not familiar with R language , 2007, Bioinform..

[22]  Z. Chang Important aspects of Toll-like receptors, ligands and their signaling pathways , 2010, Inflammation Research.

[23]  C. Chung,et al.  Targeting the Mechanisms of Resistance to Chemotherapy and Radiotherapy with the Cancer Stem Cell Hypothesis , 2010, Journal of oncology.

[24]  H. Broxmeyer,et al.  Toll-like receptor 2 mediates proliferation, survival, NF-kappaB translocation, and cytokine mRNA expression in LIF-maintained mouse embryonic stem cells. , 2010, Stem cells and development.

[25]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[26]  A. Bookout,et al.  Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways , 2003, Nuclear receptor signaling.

[27]  S. Akira,et al.  TLR signaling. , 2006, Current topics in microbiology and immunology.

[28]  H. Okano,et al.  Function of RNA-binding protein Musashi-1 in stem cells. , 2005, Experimental cell research.

[29]  M. Wicha,et al.  Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer's Inflammatory Roots , 2011, Clinical Cancer Research.

[30]  M. Karin,et al.  Role of TLR2‐dependent inflammation in metastatic progression , 2011, Annals of the New York Academy of Sciences.

[31]  Gavin Sherlock,et al.  Isolation and Molecular Characterization of Cancer Stem Cells in MMTV‐Wnt‐1 Murine Breast Tumors , 2008, Stem cells.

[32]  M. Frank,et al.  The therapeutic promise of the cancer stem cell concept. , 2010, The Journal of clinical investigation.

[33]  F. Schena,et al.  TLR2 plays a role in the activation of human resident renal stem/progenitor cells , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  G. Mor,et al.  TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence , 2013, Cell cycle.

[35]  P. Musiani,et al.  Insertion of the DNA for the 163–171 peptide of IL1β enables a DNA vaccine encoding p185neu to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice , 2001, Gene Therapy.

[36]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[37]  J. Shen,et al.  NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation , 2011, Oncogene.

[38]  R. Bals,et al.  Microbial Patterns Signaling via Toll-Like Receptors 2 and 5 Contribute to Epithelial Repair, Growth and Survival , 2008, PloS one.

[39]  Zhuo-wei Hu,et al.  Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells. , 2009, Biochemical and biophysical research communications.

[40]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[41]  Q. Zhan,et al.  Blocking TLR2 Activity Attenuates Pulmonary Metastases of Tumor , 2009, PloS one.